^
    1d
    Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) (clinicaltrials.gov)
    P2, N=20, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Mar 2028 | Trial primary completion date: Nov 2026 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IL2RA (Interleukin 2 receptor, alpha) • XIAP (X-Linked Inhibitor Of Apoptosis) • PRF1 (Perforin 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Jakafi (ruxolitinib) • methylprednisolone sodium succinate
    1d
    Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, OHSU Knight Cancer Institute
    New P1 trial
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    azacitidine • Jakafi (ruxolitinib) • cyclophosphamide
    1d
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (clinicaltrials.gov)
    P2, N=50, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Jun 2031 | Trial primary completion date: Jun 2022 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Epidaza (chidamide) • carmustine
    2d
    The efficacy and safety of ruxolitinib phosphate cream in combination therapy for refractory non-segmental vitiligo: A multicenter, real-world study (ChiCTR2600121327)
    P=N/A, N=192, China-Japan Friendship Hospital; China-Japan Friendship Hospital
    New trial • Real-world evidence
    2d
    Long-Term Efficacy and Safety of Ruxolitinib Cream as Monotherapy or Combined with Phototherapy in Non-Segmental Vitiligo: A Multicenter, Real-World Study (ChiCTR2600121220)
    P=N/A, N=200, The First Hospital of China Medical University; The First Hospital of China Medical University
    New trial • Real-world evidence
    2d
    A prospective clinical study of the combination regimen of Rabbit Anti-Human Thymocyte Immunoglobulin, Cyclosporine, Mycophenolate Mofetil, and Ruxolitinib for the prevention of graft-versus-host disease in haploidentical hematopoietic stem cell transplantation. (ChiCTR2600120679)
    P=N/A, N=40, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New trial
    |
    Jakafi (ruxolitinib) • cyclosporine
    2d
    A single-center, randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and pharmacokinetics of HL-300 ointment after single and multiple administration in healthy adult volunteers (ChiCTR2600119648)
    P1, N=36, Completed, The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University
    New P1 trial
    2d
    A Randomized, Open-label, Positive-controlled, Parallel-grouped, Multicenter Phase III Clinical Trial on the Efficacy and Safety of Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis (ChiCTR2600118347)
    P3, N=105, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS);West China Hospital of Sichuan University; Chengdu
    New P3 trial
    |
    flonoltinib
    2d
    Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease (clinicaltrials.gov)
    P2, N=14, Recruiting, University of Pennsylvania | Trial primary completion date: Dec 2028 --> Jul 2028
    Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • Sylvant (siltuximab)
    2d
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | N=59 --> 80 | Trial completion date: Mar 2029 --> Dec 2027
    Enrollment change • Trial completion date
    |
    Ojjaara (momelotinib)
    2d
    Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=41, Recruiting, Washington University School of Medicine | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Orencia (abatacept)
    3d
    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=83, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)